Therapeutic Advances in Vaccines and Immunotherapy最新文献

{"title":"Identifying higher risk subgroups of health care workers for priority vaccination against COVID-19","authors":"M. Haq, A. Rehman, M. Haq, Hala Haq, Hala Rajab, Junaid Ahmad, J. Ahmed, Saeed Anwar, Sajjad Ahmad, N. Haq","doi":"10.1177/25151355221080724","DOIUrl":"https://doi.org/10.1177/25151355221080724","url":null,"abstract":"Background: Health care workers (HCWs) are exposed to high risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection due to close contact with infected patients in hospital. The objective of this study was to estimate the seroprevalence and to identify the exposure risk of various subgroups among HCWs to prioritize them for early vaccination. Methods: This was a multicentre cross-sectional study conducted between 15 and 29 June 2020. A total of 987 HCWs were recruited randomly from two major tertiary-care hospitals of Peshawar city, Pakistan. The HCWs included doctors, nurses, paramedics and hospital support staff. The US Food and Drug Administration (FDA)–approved kit was used for the detection of SARS-CoV-2 antibodies. Results: Overall, 310 (31.4%) HCWs were seropositive for SARS-CoV-2 antibodies (95% confidence interval, CI: 28.5–34.4). Seroprevalence was higher in males (33.5%) and in age group 51–60 years (40.9%). Seropositivity increased with increasing age from 8.3% in age group ⩽20 to 40.9% in 51–60 years of age group (p < 0.05). The highest seroprevalence was identified in paramedical staff (42·5%, 95% CI: 36.6–48.6) followed by nursing staff (38·8%, 95% CI: 32.1–45.7). In logistic regression, being a male HCW led to higher risk of seropositivity (odds ratio, OR: 1.50, 95% CI: 1·06–2.13. p < 0.05) compared with female staff members. The odds of seropositivity was higher in nurses (OR: 3·47, 95% CI: 1.99–6.05. p < 0.01), paramedical staff (OR: 3·19, 95% CI: 1.93–5.28. p < 0.01) and hospital support staff (OR: 2·47, 95% CI: 1.29–4.7. p < 0.01) compared with consultants. Conclusion: Overall, our results concluded that nursing and paramedical staff are at higher risk and should be vaccinated on priority.","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43516991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance.","authors":"Joseph Fiore,&nbsp;Maribel Miranda Co-van der Mee,&nbsp;Andrés Maldonado,&nbsp;Lisa Glasser,&nbsp;Phil Watson","doi":"10.1177/25151355211057479","DOIUrl":"https://doi.org/10.1177/25151355211057479","url":null,"abstract":"<p><p>An adjuvanted recombinant zoster vaccine (RZV) is licensed for the prevention of herpes zoster. This paper reviews its safety and reactogenicity. A pooled analysis of two pivotal randomized Phase-3 trials (NCT01165177, NCT01165229) in adults ⩾50 years found that more solicited adverse events (AEs) were reported with RZV than placebo. Injection site pain was the most common solicited AE (RZV: 78.0% participants; placebo: 10.9%). Grade-3 pain occurred in 6.4% of RZV and 0.3% of placebo recipients. Myalgia, fatigue, and headache were the most commonly reported general solicited AEs (RZV: 44.7%, 44.5%, and 37.7%, respectively; placebo: 11.7%, 16.5%, and 15.5%, respectively). Most symptoms were mild to moderate in intensity with a median duration of 2-3 days. The intensity of reactogenicity symptoms did not differ substantially after the first and second vaccine doses. The pooled analysis of the pivotal Phase-3 trials did not identify any clinically relevant differences in the overall incidence of serious adverse events (SAEs), fatal AEs or potential immune-mediated diseases (pIMDs) between RZV and placebo. Reactogenicity in five studies of immunocompromised patients ⩾18 years (autologous stem cell transplant, human immunodeficiency virus, solid tumors, hematological malignancies, and renal transplant; NCT01610414, NCT01165203, NCT01798056, NCT01767467, and NCT02058589) was consistent with that observed in the pivotal Phase-3 trials. There were no clinically relevant differences between RZV and placebo in the immunocompromised populations with regard to overall incidence of SAEs, fatal AEs, pIMDs, or AEs related to patients' underlying condition. Post-marketing surveillance found that the most commonly reported AEs were consistent with the reactogenicity profile of the vaccine in clinical trials. Overall, the clinical safety data for RZV are reassuring.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211057479"},"PeriodicalIF":0.0,"publicationDate":"2021-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f2/70/10.1177_25151355211057479.PMC8734271.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39802403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic.","authors":"Charles Yap,&nbsp;Abulhassan Ali,&nbsp;Amogh Prabhakar,&nbsp;Akul Prabhakar,&nbsp;Aman Pal,&nbsp;Ying Yi Lim,&nbsp;Pramath Kakodkar","doi":"10.1177/25151355211059791","DOIUrl":"10.1177/25151355211059791","url":null,"abstract":"<p><p>Since the outbreak of the COVID-19 pandemic, there has been a rapid expansion in vaccine research focusing on exploiting the novel discoveries on the pathophysiology, genomics, and molecular biology of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although the current preventive measures are primarily socially distancing by maintaining a 1 m distance, it is supplemented using facial masks and other personal hygiene measures. However, the induction of vaccines as primary prevention is crucial to eradicating the disease to attempt restoration to normalcy. This literature review aims to describe the physiology of the vaccines and how the spike protein is used as a target to elicit an antibody-dependent immune response in humans. Furthermore, the overview, dosing strategies, efficacy, and side effects will be discussed for the notable vaccines: BioNTech/Pfizer, Moderna, AstraZeneca, Janssen, Gamaleya, and SinoVac. In addition, the development of other prominent COVID-19 vaccines will be highlighted alongside the sustainability of the vaccine-mediated immune response and current contraindications. As the research is rapidly expanding, we have looked at the association between pregnancy and COVID-19 vaccinations, in addition to the current reviews on the mixing of vaccines. Finally, the prominent emerging variants of concern are described, and the efficacy of the notable vaccines toward these variants has been summarized.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211059791"},"PeriodicalIF":0.0,"publicationDate":"2021-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/96/23/10.1177_25151355211059791.PMC8637774.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39696355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India.","authors":"Chetak Kadabasal Basavaraja,&nbsp;Juny Sebastian,&nbsp;Mandyam Dhati Ravi,&nbsp;Sheba Baby John","doi":"10.1177/25151355211055833","DOIUrl":"https://doi.org/10.1177/25151355211055833","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 vaccination program was introduced in India on 16 January 2021. The Government-issued fact sheet was the only source of information regarding Adverse Events Following Immunizations (AEFIs) for these vaccines. The objective of this study was to assess the AEFIs reported following COVID-19 vaccination in a tertiary care teaching hospital.</p><p><strong>Materials and methods: </strong>The spontaneous reporting method was used for data collection for a period of 3 months. A data collection form was designed to collect the data from the study population who reported adverse events. Collected data were analyzed and categorized by severity and seriousness. The causality assessment team performed causality assessment of the AEFIs using the World Health Organization's causality assessment algorithm.</p><p><strong>Results: </strong>A total of 11,656 doses of COVID-19 vaccine were administered at the study site during the study period, of which 9292 doses were COVISHIELD™ and 2364 doses were COVAXIN™. In all, 445 AEFIs were reported from 269 subjects with an incidence rate of 3.48%. The majority of the subjects with AEFIs belonged to the age group of 18-45 years. Out of the total 445 AEFIs, 418 AEFIs were expected as per the fact sheets, 409 with COVISHIELD™ and 9 with COVAXIN™. Most of the AEFIs [62.02% (<i>n</i> = 276)] were observed at the system organ class of 'General disorders and administration site conditions'. After the causality assessment, out of 433 AEFIs to COVISHIELD^TM vaccine, 94.22% (<i>n</i> = 408) of events were categorized to have 'consistent causal association with immunization'. Out of 12 adverse events following COVAXIN™, 8 (66.66%) events were categorized as 'consistent causal association with immunization'. All of them recovered from their adverse events without any sequelae.</p><p><strong>Conclusion: </strong>Spontaneous reporting is one of the cheapest methods that can be used for the reporting of AEFI. This method helps health care professionals to identify rare events and potential signals.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211055833"},"PeriodicalIF":0.0,"publicationDate":"2021-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/19/38/10.1177_25151355211055833.PMC8611289.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39674464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anaphylaxis after Moderna COVID-19 vaccine.","authors":"Jeremy Mayfield,&nbsp;Sumedha Bandi,&nbsp;Latha Ganti,&nbsp;Jose Rubero","doi":"10.1177/25151355211048418","DOIUrl":"10.1177/25151355211048418","url":null,"abstract":"<p><p>The authors of this article report on a case of a patient who presented to the emergency department (ED) in anaphylaxis after receiving the Moderna® COVID-19 vaccine. The patient was hypoxic, with diffuse wheezing bilaterally to auscultation, flush skin, swollen face, and the feeling of her throat closing. Anaphylaxis can have wide range of presentation, the key is recognizing the symptoms and treating early. The incidence of anaphylaxis from COVID-19 vaccine is not well documented to date.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211048418"},"PeriodicalIF":0.0,"publicationDate":"2021-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/0e/10.1177_25151355211048418.PMC8558796.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39693692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving vaccine-related health literacy in parents: comparison on the readability of CDC Vaccine Information Statements (VIS) and Health and Human Services (HHS) patient-facing vaccine literature.","authors":"Beverley C Millar,&nbsp;John E Moore","doi":"10.1177/25151355211047521","DOIUrl":"https://doi.org/10.1177/25151355211047521","url":null,"abstract":"","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211047521"},"PeriodicalIF":0.0,"publicationDate":"2021-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/89/60/10.1177_25151355211047521.PMC8485266.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39507124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine hesitancy in Africa: causes and strategies to the rescue.","authors":"Abdullahi Tunde Aborode,&nbsp;Emmanuel Adebowale Fajemisin,&nbsp;Osmond C Ekwebelem,&nbsp;Christos Tsagkaris,&nbsp;Edeh Abigael Taiwo,&nbsp;Olivier Uwishema,&nbsp;Oluwasola Oluwabusayo Awoniyi,&nbsp;Shoaib Ahmad,&nbsp;Mohammad Yasir Essar,&nbsp;Irem Adanur,&nbsp;Ismaeel Yunusa","doi":"10.1177/25151355211047514","DOIUrl":"https://doi.org/10.1177/25151355211047514","url":null,"abstract":"Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Dear Editor,","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211047514"},"PeriodicalIF":0.0,"publicationDate":"2021-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/45/10.1177_25151355211047514.PMC8481750.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39507123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transdermal approaches to vaccinations in the COVID-19 pandemic era.","authors":"Michelle S Lee,&nbsp;Catherina X Pan,&nbsp;Vinod E Nambudiri","doi":"10.1177/25151355211039073","DOIUrl":"https://doi.org/10.1177/25151355211039073","url":null,"abstract":"<p><p>The COVID-19 pandemic has necessitated rapid vaccine development for the control of the disease. Most vaccinations, including those currently approved for COVID-19 are administered intramuscularly and subcutaneously using hypodermic needles. However, there are several disadvantages including pain and fear of needlesticks, the need for two doses, the need for trained health care professionals for vaccine administration, and barriers to global distribution given the need for cold supply chain. Recently, transdermal techniques have been under investigation for vaccines including COVID-19. Microneedle array technology utilizes multiple microscopic projections from a plate which delivers a vaccine in the form of a patch placed on the skin, allowing for painless antigen delivery with improved immune response. In this review, we discuss challenges of existing vaccines and review the literature on the science behind transdermal vaccines including microneedles, current evidence of application in infectious diseases including COVID-19, and considerations for implementation and global access.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211039073"},"PeriodicalIF":0.0,"publicationDate":"2021-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/07/75/10.1177_25151355211039073.PMC8384302.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39358949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of educational intervention on the best immunization practices among practicing health care professionals in a south Indian city.","authors":"Juny Sebastian,&nbsp;Gurumurthy Parthasarathi,&nbsp;Mandyam Dhati Ravi","doi":"10.1177/25151355211032590","DOIUrl":"https://doi.org/10.1177/25151355211032590","url":null,"abstract":"<p><strong>Background and aims: </strong>Maintaining the quality and safety of immunization is as important as the efficacy of vaccines in vaccine-preventable diseases (VPD) programs. The aim of this study was to determine the problems associated with different stages of vaccine use and to assess the outcome of an educational intervention on safety and quality use of vaccines among health care providers.</p><p><strong>Methods: </strong>A pilot prospective interventional study was conducted over a period of 2 years at 271 sites in Mysuru, India. The study population was health care professionals (HCPs) involved in immunization and a sample of parents (one per site). A validated questionnaire was used as a study tool. An educational intervention on best immunization practice was conducted for the enrolled HCPs and the impact of the educational intervention was assessed using the study tool after 3 weeks.</p><p><strong>Results: </strong>The total number of the study population was 594 (323 HCPs and 271 parents). Of these, 41.49% were working at community health care facility and 33.13% were enrolled from primary care centers. There were statistically significant improvements in post interventional assessment of all stages of the immunization process including storage (<i>p</i> -0.001), transportation (<i>p</i> -0.001), administration (<i>p</i> 0.001), monitoring and reporting of adverse events following immunization (AEFIs) (<i>p</i> -0.001), knowledge of AEFIs (<i>p</i> 0.001), and HCP-parent communication (<i>p</i> 0.001). AEFI reporting improved by 30% in the post education phase.</p><p><strong>Conclusion: </strong>Continuous education and motivation can result in positive behavioral changes on best immunization practices amongst HCPs involved in immunization, which may help to improve and maintain the safety and quality use of vaccines in immunization centers irrespective of the type of facility.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211032590"},"PeriodicalIF":0.0,"publicationDate":"2021-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/25151355211032590","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39309834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnant women's hepatitis B vaccination coverage in Nigeria: a national pilot cross-sectional study.","authors":"George Uchenna Eleje, Godwin Otuodichinma Akaba, Ikechukwu Innocent Mbachu, Ayyuba Rabiu, Olabisi Morebise Loto, Hadiza Abdullahi Usman, Preye Owen Fiebai, Rebecca Chinyelu Chukwuanukwu, Ngozi Nneka Joe-Ikechebelu, Chike Henry Nwankwo, Stephen Okoroafor Kalu, Chinyere Ukamaka Onubogu, Chukwuanugo Nkemakonam Ogbuagu, Shirley Nneka Chukwurah, Chinwe Elizabeth Uzochukwu, Samuel Oluwagbenga Inuyomi, Bukola Abimbola Adesoji, Uchenna Chukwunonso Ogwaluonye, Sussan Ifeyinwa Nweje, Richard Obinwanne Egeonu, Odion Emmanuel Igue, Chiamaka Henrietta Jibuaku, Prince Ogbonnia Aja, Chiamaka Perpetua Chidozie, Hadiza Sani Ibrahim, Fatima Ele Aliyu, Aisha Ismaila Numan, Ogbonna Dennis Okoro, Solace Amechi Omoruyi, Ijeoma Chioma Oppah, Ubong Inyang Anyang, Aishat Ahmed, Osita Samuel Umeononihu, Eric Okechukwu Umeh, Ekene Agatha Emeka, Arinze Anthony Onwuegbuna, Emeka Philip Igbodike, Ifeoma Clara Ajuba, Ibrahim Adamu Yakasai, Oliver Chukwujekwu Ezechi, Joseph Ifeanyichukwu Ikechebelu","doi":"10.1177/25151355211032595","DOIUrl":"10.1177/25151355211032595","url":null,"abstract":"<p><strong>Objective: </strong>To determine the hepatitis B vaccination coverage, full-dose (⩾3) coverage and the associated factors affecting uptake among pregnant women.</p><p><strong>Methods: </strong>This was a cross-sectional study among pregnant women attending antenatal care in six tertiary hospitals across all the geopolitical zones of Nigeria. Pregnant women who consented to the study completed screening questions about their hepatitis B vaccination status and coverage. The main outcome measures were hepatitis B vaccination coverage rate, dose, and factors affecting uptake. Bivariate analysis was performed by the chi-square test and conditional logistic regression analysis was used to determine variables associated with uptake of the vaccination. Odds ratios (ORs) and adjusted odds ratios (aORs) were calculated and statistical significance was accepted when <i>p</i>-value was < 0.05.</p><p><strong>Results: </strong>Of 159 pregnant women who completed the interview questions, 21 [13.2%, 95% confidence interval (CI) 7.9-18.5%] were vaccinated for hepatitis B for one to three doses. The numbers of doses received were: three doses (8/159, 5.0%), two doses (5/159, 3.1%), and one dose (8/159, 5.0%). The reasons for non-uptake of vaccination included: lack of awareness of the vaccine 83/138 (60.1%), inadequate access to vaccine 11/138 (8.0%), and positivity to hepatitis B virus 10/138 (7.2%). The uptake of hepatitis B vaccination was significantly affected by the level of education (OR 0.284, 95% CI 0.08-1.01, <i>p</i> = 0.041), but in multivariable logistic regression, adjusted for confounders, the association between hepatitis B vaccination and participants' level of education (aOR 3.09; 95% CI 0.95-10.16; <i>p</i> = 0.061) did not remain significant.</p><p><strong>Conclusions: </strong>In Nigeria, the national hepatitis B vaccination coverage among pregnant women appears poor, with the full-dose coverage even poorer. The level of education was not positively associated with uptake of hepatitis B vaccination, while lack of awareness of the vaccine was the commonest reason for non-uptake.</p><p><strong>Funding: </strong>TETFund National Research Fund 2019 (grant number TETFund/DR&D/CE/NRF/STI/33).</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"9 ","pages":"25151355211032595"},"PeriodicalIF":0.0,"publicationDate":"2021-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/97/a3/10.1177_25151355211032595.PMC8327013.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39309836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}